Low-Dose Allergen-Specific Immunotherapy Induces Tolerance in a Murine Model of Shrimp Allergy

Nicki Yat Hin Leung, Christine Yee Yan Wai, Shang An Shu, Christopher C. Chang, Ka Hou Chu, Patrick S Leung

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The efficacy and safety of allergen-specific immunotherapy (AIT) are highly dose-dependent. Methods: We investigated the dosage effects of AIT and the underlying mechanisms in a murine model of shrimp hypersensitivity. BALB/c mice were sensitized with recombinant shrimp allergen rMet e 1 and challenged orally with a high dose of rMet e 1 to elicit an allergic response. These sensitized mice were then treated with a low (0.01 mg), medium (0.05 mg), or high dosage (0.1 mg) of rMet e 1 intraperitoneally before receiving a second oral challenge. The allergic responses and immunological changes in the gut were compared between animals receiving different dosages. Results: We found that all sensitized mice that received rMet e 1 immunotherapy were desensitized, regardless of the dosage, and protected at the second oral challenge. Nevertheless, the mice in the high-dosage group experienced severe systemic reactions during the treatment phase. In contrast, regulatory T (Treg) cell-associated genes were upregulated only in the low- and medium-dosage groups, and Foxp3+ cells were more abundant in the gut lymphoid tissues than in the high-dosage group. Conclusions: Our results demonstrate that low-dosage immunotherapy favors the induction of local Foxp3+ Treg cells and the upregulation of regulatory cytokines. The safety advantages and long-term efficacy of low-dosage immunotherapy should be taken into consideration when developing immunotherapy dose schedules.

Original languageEnglish (US)
Pages (from-to)86-96
Number of pages11
JournalInternational Archives of Allergy and Immunology
DOIs
StateAccepted/In press - Oct 25 2017

Fingerprint

Immunologic Desensitization
Immunotherapy
Hypersensitivity
Regulatory T-Lymphocytes
Safety
Lymphoid Tissue
Allergens
Appointments and Schedules
Up-Regulation
Cytokines
Genes

Keywords

  • Desensitization
  • Dosage
  • Foxp3
  • Regulatory T cells
  • Tropomyosin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Low-Dose Allergen-Specific Immunotherapy Induces Tolerance in a Murine Model of Shrimp Allergy. / Leung, Nicki Yat Hin; Wai, Christine Yee Yan; Shu, Shang An; Chang, Christopher C.; Chu, Ka Hou; Leung, Patrick S.

In: International Archives of Allergy and Immunology, 25.10.2017, p. 86-96.

Research output: Contribution to journalArticle

Leung, Nicki Yat Hin ; Wai, Christine Yee Yan ; Shu, Shang An ; Chang, Christopher C. ; Chu, Ka Hou ; Leung, Patrick S. / Low-Dose Allergen-Specific Immunotherapy Induces Tolerance in a Murine Model of Shrimp Allergy. In: International Archives of Allergy and Immunology. 2017 ; pp. 86-96.
@article{ae45bd5c4d2c4574984458fff108c555,
title = "Low-Dose Allergen-Specific Immunotherapy Induces Tolerance in a Murine Model of Shrimp Allergy",
abstract = "Background: The efficacy and safety of allergen-specific immunotherapy (AIT) are highly dose-dependent. Methods: We investigated the dosage effects of AIT and the underlying mechanisms in a murine model of shrimp hypersensitivity. BALB/c mice were sensitized with recombinant shrimp allergen rMet e 1 and challenged orally with a high dose of rMet e 1 to elicit an allergic response. These sensitized mice were then treated with a low (0.01 mg), medium (0.05 mg), or high dosage (0.1 mg) of rMet e 1 intraperitoneally before receiving a second oral challenge. The allergic responses and immunological changes in the gut were compared between animals receiving different dosages. Results: We found that all sensitized mice that received rMet e 1 immunotherapy were desensitized, regardless of the dosage, and protected at the second oral challenge. Nevertheless, the mice in the high-dosage group experienced severe systemic reactions during the treatment phase. In contrast, regulatory T (Treg) cell-associated genes were upregulated only in the low- and medium-dosage groups, and Foxp3+ cells were more abundant in the gut lymphoid tissues than in the high-dosage group. Conclusions: Our results demonstrate that low-dosage immunotherapy favors the induction of local Foxp3+ Treg cells and the upregulation of regulatory cytokines. The safety advantages and long-term efficacy of low-dosage immunotherapy should be taken into consideration when developing immunotherapy dose schedules.",
keywords = "Desensitization, Dosage, Foxp3, Regulatory T cells, Tropomyosin",
author = "Leung, {Nicki Yat Hin} and Wai, {Christine Yee Yan} and Shu, {Shang An} and Chang, {Christopher C.} and Chu, {Ka Hou} and Leung, {Patrick S}",
year = "2017",
month = "10",
day = "25",
doi = "10.1159/000479694",
language = "English (US)",
pages = "86--96",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Low-Dose Allergen-Specific Immunotherapy Induces Tolerance in a Murine Model of Shrimp Allergy

AU - Leung, Nicki Yat Hin

AU - Wai, Christine Yee Yan

AU - Shu, Shang An

AU - Chang, Christopher C.

AU - Chu, Ka Hou

AU - Leung, Patrick S

PY - 2017/10/25

Y1 - 2017/10/25

N2 - Background: The efficacy and safety of allergen-specific immunotherapy (AIT) are highly dose-dependent. Methods: We investigated the dosage effects of AIT and the underlying mechanisms in a murine model of shrimp hypersensitivity. BALB/c mice were sensitized with recombinant shrimp allergen rMet e 1 and challenged orally with a high dose of rMet e 1 to elicit an allergic response. These sensitized mice were then treated with a low (0.01 mg), medium (0.05 mg), or high dosage (0.1 mg) of rMet e 1 intraperitoneally before receiving a second oral challenge. The allergic responses and immunological changes in the gut were compared between animals receiving different dosages. Results: We found that all sensitized mice that received rMet e 1 immunotherapy were desensitized, regardless of the dosage, and protected at the second oral challenge. Nevertheless, the mice in the high-dosage group experienced severe systemic reactions during the treatment phase. In contrast, regulatory T (Treg) cell-associated genes were upregulated only in the low- and medium-dosage groups, and Foxp3+ cells were more abundant in the gut lymphoid tissues than in the high-dosage group. Conclusions: Our results demonstrate that low-dosage immunotherapy favors the induction of local Foxp3+ Treg cells and the upregulation of regulatory cytokines. The safety advantages and long-term efficacy of low-dosage immunotherapy should be taken into consideration when developing immunotherapy dose schedules.

AB - Background: The efficacy and safety of allergen-specific immunotherapy (AIT) are highly dose-dependent. Methods: We investigated the dosage effects of AIT and the underlying mechanisms in a murine model of shrimp hypersensitivity. BALB/c mice were sensitized with recombinant shrimp allergen rMet e 1 and challenged orally with a high dose of rMet e 1 to elicit an allergic response. These sensitized mice were then treated with a low (0.01 mg), medium (0.05 mg), or high dosage (0.1 mg) of rMet e 1 intraperitoneally before receiving a second oral challenge. The allergic responses and immunological changes in the gut were compared between animals receiving different dosages. Results: We found that all sensitized mice that received rMet e 1 immunotherapy were desensitized, regardless of the dosage, and protected at the second oral challenge. Nevertheless, the mice in the high-dosage group experienced severe systemic reactions during the treatment phase. In contrast, regulatory T (Treg) cell-associated genes were upregulated only in the low- and medium-dosage groups, and Foxp3+ cells were more abundant in the gut lymphoid tissues than in the high-dosage group. Conclusions: Our results demonstrate that low-dosage immunotherapy favors the induction of local Foxp3+ Treg cells and the upregulation of regulatory cytokines. The safety advantages and long-term efficacy of low-dosage immunotherapy should be taken into consideration when developing immunotherapy dose schedules.

KW - Desensitization

KW - Dosage

KW - Foxp3

KW - Regulatory T cells

KW - Tropomyosin

UR - http://www.scopus.com/inward/record.url?scp=85032354096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032354096&partnerID=8YFLogxK

U2 - 10.1159/000479694

DO - 10.1159/000479694

M3 - Article

SP - 86

EP - 96

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

ER -